{
    "2021-08-27": [
        [
            {
                "time": "2023-10-05",
                "original_text": "UPDATE 1-U.S. resumes supply of Lilly's COVID-19 antibody combo to some states",
                "features": {
                    "keywords": [
                        "resumes supply",
                        "Lilly's",
                        "COVID-19",
                        "antibody combo"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "U.S. resumes supply of Lilly's COVID-19 antibody combo to some states",
                "features": {
                    "keywords": [
                        "resumes supply",
                        "Lilly's",
                        "COVID-19",
                        "antibody combo"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Boehringer",
                        "Jardiance",
                        "Heart Failure"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Landmark trial demonstrates JardianceÂ® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction",
                "features": {
                    "keywords": [
                        "Landmark trial",
                        "Jardiance",
                        "heart failure",
                        "statistically significant",
                        "improvement"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "This Potential Indication Could Mean Profit for Eli Lilly Investors",
                "features": {
                    "keywords": [
                        "Potential Indication",
                        "Profit",
                        "Eli Lilly",
                        "Investors"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}